Catalyst Biosciences Inc. (CBIO)
0.51
-0.02 (-2.89%)
At close: Oct 30, 2023, 8:00 PM
-2.89% (1D)
| Bid | n/a |
| Market Cap | 19.42M |
| Revenue (ttm) | -794K |
| Net Income (ttm) | -44.24M |
| EPS (ttm) | -20.7 |
| PE Ratio (ttm) | -0.02470048309178744 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 460,710 |
| Avg. Volume (20D) | 437,269 |
| Open | 0.57 |
| Previous Close | 0.53 |
| Day's Range | 0.48 - 0.58 |
| 52-Week Range | 0.19 - 8.69 |
| Beta | 1.29 |
About CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD);...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 12, 2006
Employees 7
Stock Exchange NASDAQ
Ticker Symbol CBIO